|Bid||6.16 x 1200|
|Ask||6.58 x 800|
|Day's Range||6.03 - 6.22|
|52 Week Range||4.50 - 6.70|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||11.22|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
REHOVOT, Israel, April 16, 2019 -- Kamada Ltd. (Nasdaq & TASE: KMDA), a plasma-derived protein therapeutics company, today announced receipt of a letter from the U.S. Food.
Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.
Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.
BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.
FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.
Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.
Puma Biotech (PBYI) increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.
Puma Biotech (PBYI) out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.
Seattle Genetics (SGEN) and partner Genmab end enrollment in the phase II study on tisotumab vedotin for treating patients with advanced/metastatic cervical cancer.
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
Zacks.com featured expert Kevin Matras highlights: Kamada, Plantronics, SkyWest, SYNNEX and Walker & Dunlop
Agios' (AGIO) first wholly owned precision medicine, Tibsovo, has been picking up the sales pace since its FDA approval last year with strong sequential growth delivered in Q4.
Agios (AGIO) receives a Breakthrough Therapy designation for Tibsovo combo to treat the newly diagnosed acute myeloid leukemia in adult patients with an IDH1 mutation.
Zacks.com featured expert Kevin Matras highlights: Kamada, Herc, Medifast, SkyWest and SP Plus
Looking beyond profits to a company's cash position will be far more rewarding as this highlights its true financial health.